160
Participants
Start Date
January 16, 2020
Primary Completion Date
August 30, 2021
Study Completion Date
November 22, 2021
Dupilumab SAR231893
Pharmaceutical form:Injection solution Route of administration: Subcutaneous
Placebo
Pharmaceutical form:Injection solution Route of administration: Subcutaneous
Moisturizers
"Pharmaceutical form:~Route of administration: Topical"
Low to medium potent topical corticosteroids
"Pharmaceutical form:~Route of administration: Topical"
Topical calcineurin inhibitors
"Pharmaceutical form:~Route of administration: Topical"
Investigational Site Number :1580006, Kaohsiung City
Investigational Site Number :3480004, Debrecen
Investigational Site Number :3480002, Orosháza
Investigational Site Number :3480003, Szeged
Investigational Site Number :3480005, Pécs
Investigational Site Number :1580001, Taipei
Investigational Site Number :1580002, Taipei
Investigational Site Number :7240004, Córdoba
Investigational Site Number :4100003, Bucheon-si
Investigational Site Number :3800001, Rozzano
Investigational Site Number :3800002, Milan
Investigational Site Number :8400003, Baltimore
Investigational Site Number :4100007, Incheon
Investigational Site Number :7240007, Madrid
Investigational Site Number :2500001, Brest
Investigational Site Number :1580005, Hsinchu
Investigational Site Number :2500003, Toulouse
Investigational Site Number :8400005, Pembroke Pines
Investigational Site Number :2500007, Bordeaux
Investigational Site Number :7240008, Santullano
Investigational Site Number :7240001, Pontevedra
Investigational Site Number :7240003, Valencia
Investigational Site Number :8400002, Plainfield
Investigational Site Number :4100002, Busan
Investigational Site Number :7240002, Zaragoza
Investigational Site Number :2500005, Reims
Investigational Site Number :2500002, Lille
Investigational Site Number :3800004, Ancona
Investigational Site Number :2500006, Lyon
Investigational Site Number :2500008, Le Mans
Investigational Site Number :8400054, Fort Smith
Investigational Site Number :2500004, Paris
Investigational Site Number :8400001, Sugar Land
Investigational Site Number :3800003, Catanzaro
Investigational Site Number :8400008, Sacramento
Investigational Site Number :1520005, Valdivia
Investigational Site Number :1520006, Osorno
Investigational Site Number :1520003, Santiago
Investigational Site Number :1520001, Santiago
Investigational Site Number :1520004, Santiago
Investigational Site Number :8400006, East Windsor
Investigational Site Number :1240002, Calgary
Investigational Site Number :1240006, Surrey
Investigational Site Number :1240007, Markham
Investigational Site Number :1240008, Newmarket
Investigational Site Number :1240001, Toronto
Investigational Site Number :1240009, Saskatoon
Investigational Site Number :1520002, Santiago
Investigational Site Number :1580008, Taichung
Investigational Site Number :6200001, Coimbra
Investigational Site Number :6200002, Lisbon
Investigational Site Number :6200003, Porto
Investigational Site Number :4100005, Seoul
Investigational Site Number :4100001, Seoul
Investigational Site Number :4100006, Seoul
Investigational Site Number :7240009, Badalona
Investigational Site Number :8260001, Redhill
Lead Sponsor
Regeneron Pharmaceuticals
INDUSTRY
Sanofi
INDUSTRY